Could a common Alzheimer's drug sharpen minds in down syndrome?

NCT ID NCT07531940

First seen Apr 23, 2026 · Last updated May 14, 2026 · Updated 2 times

Summary

This early-stage study will test whether higher-than-normal doses of memantine, a drug already approved for Alzheimer's, are safe and might improve memory and thinking in 25 adolescents and young adults with Down syndrome. Participants will try three different doses to find the best balance of safety and potential benefit. The goal is to gather enough information to plan a larger, more definitive study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DOWN SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospitals Case Medical Center

    Cleveland, Ohio, 44106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.